Literature DB >> 19563533

Autocrine amplification loop in statin-induced apoptosis of human melanoma cells.

C Minichsdorfer1, M Hohenegger.   

Abstract

BACKGROUND AND
PURPOSE: Beside their cholesterol lowering effect, statins exert pleiotropic effects, which include anti-inflammatory, immunosuppressive and anti-proliferative actions. In higher concentrations, statins trigger apoptosis in primary cells and tumour cells. In particular, melanoma cells have been found to be susceptible to statin-induced apoptosis, although only after longer incubation times. The molecular mechanisms behind this delayed drug-induced apoptosis are still unclear. EXPERIMENTAL APPROACH: The human melanoma A375 and 518A2 cell lines were exposed to various statins in a time-dependent and dose-dependent manner, and indicators of apoptosis, caspase activity and individual apoptotic pathways were analysed for 3-hydroxy-3-methylglutaryl-coenzyme A reductase dependent and independent effects. KEY
RESULTS: Kinetic analysis of statin-induced apoptosis revealed an apoptotic burst for exposure times longer than 24 h. While the extrinsic pathway was not activated within 24 h, longer incubation times corroborated amplification of the mitochondrial pathway with significant activation of caspase 8. Continuous refreshing of the simvastatin-containing medium abrogated the mitochondrial amplification loop via caspase 8. Moreover, conditional medium, supplemented with mevalonic acid in order to nullify a possible contamination by statins, significantly triggered caspase 8 activity. Fas ligand was excluded as a possible candidate to account for the statin-induced autocrine amplification loop. CONCLUSIONS AND IMPLICATIONS: Simvastatin and atorvastatin are capable of triggering an 'autocrine' suicide factor, which amplifies apoptosis via the extrinsic pathway in human melanoma cells. This pro-apoptotic stimulus implies possible therapeutic potential and may guide feasibility for more potent statins in anti-cancer strategies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19563533      PMCID: PMC2743847          DOI: 10.1111/j.1476-5381.2009.00298.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  36 in total

1.  Statins and cancer risk: a meta-analysis.

Authors:  Krista M Dale; Craig I Coleman; Nickole N Henyan; Jeffrey Kluger; C Michael White
Journal:  JAMA       Date:  2006-01-04       Impact factor: 56.272

2.  Delineation of myotoxicity induced by 3-hydroxy-3-methylglutaryl CoA reductase inhibitors in human skeletal muscle cells.

Authors:  Julia Sacher; Lukas Weigl; Martin Werner; Csaba Szegedi; Martin Hohenegger
Journal:  J Pharmacol Exp Ther       Date:  2005-05-24       Impact factor: 4.030

Review 3.  Apoptotic pathways: ten minutes to dead.

Authors:  Douglas R Green
Journal:  Cell       Date:  2005-06-03       Impact factor: 41.582

Review 4.  Statins and cancer prevention.

Authors:  Marie-France Demierre; Peter D R Higgins; Stephen B Gruber; Ernest Hawk; Scott M Lippman
Journal:  Nat Rev Cancer       Date:  2005-12       Impact factor: 60.716

Review 5.  Tumor counterattack: fact or fiction?

Authors:  Frederik H Igney; Peter H Krammer
Journal:  Cancer Immunol Immunother       Date:  2005-05-12       Impact factor: 6.968

6.  Lovastatin-induced apoptosis in human melanoma cell lines.

Authors:  Yiqun G Shellman; Deborah Ribble; Leslie Miller; John Gendall; Kayleen Vanbuskirk; Desiree Kelly; David A Norris; Robert P Dellavalle
Journal:  Melanoma Res       Date:  2005-04       Impact factor: 3.599

Review 7.  Cholesterol-independent effects of statins and new therapeutic targets: ischemic stroke and dementia.

Authors:  Takashi Miida; Satoshi Hirayama; Yuichi Nakamura
Journal:  J Atheroscler Thromb       Date:  2004       Impact factor: 4.928

8.  Dose-finding study of high-dose simvastatin combined with standard chemotherapy in patients with relapsed or refractory myeloma or lymphoma.

Authors:  Ellen van der Spek; Andries C Bloem; Niels W C J van de Donk; Lijnie H Bogers; René van der Griend; Mark H Kramer; Okke de Weerdt; Shulamiet Wittebol; Henk M Lokhorst
Journal:  Haematologica       Date:  2006-04       Impact factor: 9.941

9.  Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer.

Authors:  A Thibault; D Samid; A C Tompkins; W D Figg; M R Cooper; R J Hohl; J Trepel; B Liang; N Patronas; D J Venzon; E Reed; C E Myers
Journal:  Clin Cancer Res       Date:  1996-03       Impact factor: 12.531

10.  WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis.

Authors:  W S el-Deiry; J W Harper; P M O'Connor; V E Velculescu; C E Canman; J Jackman; J A Pietenpol; M Burrell; D E Hill; Y Wang
Journal:  Cancer Res       Date:  1994-03-01       Impact factor: 12.701

View more
  13 in total

1.  Can statin therapy reduce the risk of melanoma? A meta-analysis of randomized controlled trials.

Authors:  Stefanos Bonovas; Georgios Nikolopoulos; Kalitsa Filioussi; Evangelia Peponi; Pantelis Bagos; Nikolaos M Sitaras
Journal:  Eur J Epidemiol       Date:  2009-10-21       Impact factor: 8.082

2.  Statin use and risk of skin cancer.

Authors:  Brian M Lin; Wen-Qing Li; Eunyoung Cho; Gary C Curhan; Abrar A Qureshi
Journal:  J Am Acad Dermatol       Date:  2017-12-05       Impact factor: 11.527

3.  Prospective analysis of association between use of statins and melanoma risk in the Women's Health Initiative.

Authors:  Deepa Jagtap; Carol A Rosenberg; Lisa W Martin; Mary Pettinger; Janardan Khandekar; Dorothy Lane; Ira Ockene; Michael S Simon
Journal:  Cancer       Date:  2012-03-20       Impact factor: 6.860

4.  Regulation of apoptosis in human melanoma and neuroblastoma cells by statins, sodium arsenite and TRAIL: a role of combined treatment versus monotherapy.

Authors:  Vladimir N Ivanov; Tom K Hei
Journal:  Apoptosis       Date:  2011-12       Impact factor: 4.677

5.  Tocilizumab unmasks a stage-dependent interleukin-6 component in statin-induced apoptosis of metastatic melanoma cells.

Authors:  Christoph Minichsdorfer; Christine Wasinger; Evelyn Sieczkowski; Bihter Atil; Martin Hohenegger
Journal:  Melanoma Res       Date:  2015-08       Impact factor: 3.599

6.  Anti-proliferative and cytotoxic activity of rosuvastatin against melanoma cells.

Authors:  Malgorzata Maj; Rafal Czajkowski; Barbara Zegarska; Bogna Kowaliszyn; Marta Pokrywczynska; Tomasz Drewa
Journal:  Postepy Dermatol Alergol       Date:  2016-08-16       Impact factor: 1.837

7.  In vitro and in vivo downregulation of the ATP binding cassette transporter B1 by the HMG-CoA reductase inhibitor simvastatin.

Authors:  Bihter Atil; Evelyn Berger-Sieczkowski; Johanna Bardy; Martin Werner; Martin Hohenegger
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-08-30       Impact factor: 3.000

8.  Autocrine secretion of 15d-PGJ2 mediates simvastatin-induced apoptotic burst in human metastatic melanoma cells.

Authors:  Christine Wasinger; Martin Künzl; Christoph Minichsdorfer; Christoph Höller; Maria Zellner; Martin Hohenegger
Journal:  Br J Pharmacol       Date:  2014-12       Impact factor: 8.739

9.  Simvastatin-induced compartmentalisation of doxorubicin sharpens up nuclear topoisomerase II inhibition in human rhabdomyosarcoma cells.

Authors:  Martin Werner; Bihter Atil; Evelyn Sieczkowski; Peter Chiba; Martin Hohenegger
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-04-07       Impact factor: 3.000

10.  Statin use and its effect on all-cause mortality of melanoma patients: a population-based Dutch cohort study.

Authors:  Elisabeth Livingstone; Loes M Hollestein; Myrthe P P van Herk-Sukel; Lonneke van de Poll-Franse; Arjen Joosse; Bastian Schilling; Tamar Nijsten; Dirk Schadendorf; Esther de Vries
Journal:  Cancer Med       Date:  2014-06-17       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.